Categories: Health

Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHASKA, Minn., Jan. 16, 2026 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on January 14, 2026, the Lifecore compensation committee approved grants under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) of restricted stock unit (“RSU”) awards with respect to an aggregate 1,738 shares of its common stock and stock options for an aggregate 8,775 shares of common stock to two newly hired employees of Lifecore. The RSU award and stock options were granted on January 14, 2026, pursuant to the offer letters between Lifecore and each employee, and as a material inducement to each employee joining Lifecore.

The RSU awards and stock options were approved by Lifecore’s compensation committee and were granted as inducement equity awards in accordance with Nasdaq Listing Rule 5635(c)(4) under the Inducement Plan.

The RSUs will vest and be settled on the third anniversary of the grant date, subject to continued employment. The stock options have an exercise price equal to Fair Market Value (as defined in the Inducement Plan) on the grant date and will vest as to one-third of the shares on the first anniversary of the grant date and as to 1/36th of the shares on each monthly grant date thereafter, subject to continued employment. The stock options have a seven-year term. The RSU award and stock options are each governed by an award agreement and the Inducement Plan.

About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.



GlobeNews Wire

Recent Posts

Mantle to Introduce New RWA Trading Capabilities and Sports Fan Economies with Fluxion, VOOI, SCOR in Upcoming Jan Livestream

DUBAI, UAE, Jan. 16, 2026 /PRNewswire/ -- Mantle, the high-performance distribution and liquidity layer connecting…

53 minutes ago

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

January 16, 2026 17:05 ET  | Source: Annexon Biosciences BRISBANE, Calif., Jan. 16, 2026 (GLOBE…

3 hours ago

Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency

January 16, 2026 16:30 ET  | Source: Cellyan Biotechnology Co., Ltd HONG KONG, Jan. 16,…

3 hours ago

/C O R R E C T I O N — New York Stock Exchange/

In the news release, NYSE Content Advisory: Pre-Market Update + Singapore Software Firm TechCreate Rings…

4 hours ago

Bybit Opens BYUSDT to All Users After Successful VIP Launch

DUBAI, UAE, Jan. 16, 2026 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency exchange by trading volume,…

4 hours ago

Sunmi Cuts Clutter and Boosts Speed with New All-in-One Mobile Terminal & Scanner-Printer

SINGAPORE, Jan. 16, 2026 /PRNewswire/ -- Business Challenge: Stores today face dual pressures: the need for…

4 hours ago